| Schedule of Reconciliation Including Such Costs to Our Consolidated Net Loss |
Based on certain significant period cost information regularly provided to our Chief Operating Decision Maker, following is a reconciliation of such costs to our consolidated net income (loss) for the three and nine months ended September 30, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended September 30, |
|
|
Nine months ended September 30, |
|
($ in thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
$ |
32,185 |
|
|
$ |
20,061 |
|
|
$ |
66,352 |
|
|
$ |
54,130 |
|
Service |
|
|
628 |
|
|
|
5,969 |
|
|
|
9,883 |
|
|
|
12,696 |
|
Total revenue |
|
|
32,813 |
|
|
|
26,030 |
|
|
|
76,235 |
|
|
|
66,826 |
|
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
|
31,397 |
|
|
|
18,550 |
|
|
|
69,810 |
|
|
|
57,537 |
|
Service |
|
|
(485 |
) |
|
|
5,886 |
|
|
|
7,985 |
|
|
|
15,061 |
|
Total cost of revenue |
|
|
30,912 |
|
|
|
24,436 |
|
|
|
77,795 |
|
|
|
72,598 |
|
Gross profit (loss) |
|
|
1,901 |
|
|
|
1,594 |
|
|
|
(1,560 |
) |
|
|
(5,772 |
) |
Less: significant segment period costs: |
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
(1,815 |
) |
|
|
(880 |
) |
|
|
(6,026 |
) |
|
|
(1,605 |
) |
Personnel costs (excluding stock-based compensation) |
|
|
(4,391 |
) |
|
|
(3,663 |
) |
|
|
(13,528 |
) |
|
|
(11,489 |
) |
Credit loss credits (provisions) |
|
|
(54 |
) |
|
|
(374 |
) |
|
|
(16 |
) |
|
|
(566 |
) |
Other segment expenses(1) |
|
|
(4,181 |
) |
|
|
(4,382 |
) |
|
|
(13,195 |
) |
|
|
(10,332 |
) |
Interest expense |
|
|
(4,292 |
) |
|
|
(1,988 |
) |
|
|
(12,521 |
) |
|
|
(3,430 |
) |
Interest income |
|
|
99 |
|
|
|
6 |
|
|
|
109 |
|
|
|
17 |
|
Gain from disposal of investment in unconsolidated subsidiary |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3,204 |
|
Gain on sale of Atlas |
|
|
— |
|
|
|
90 |
|
|
|
26 |
|
|
|
140 |
|
Gain (loss) from change in fair value of warrant liability |
|
|
19,480 |
|
|
|
(16,066 |
) |
|
|
59,335 |
|
|
|
(14,298 |
) |
Loss on extinguishment of debt |
|
|
— |
|
|
|
(173 |
) |
|
|
— |
|
|
|
(173 |
) |
Other income, net |
|
|
165 |
|
|
|
35 |
|
|
|
175 |
|
|
|
110 |
|
Income from unconsolidated subsidiary |
|
|
— |
|
|
|
1,907 |
|
|
|
— |
|
|
|
1,344 |
|
Provision for income taxes |
|
|
(210 |
) |
|
|
(44 |
) |
|
|
(622 |
) |
|
|
(337 |
) |
Net income (loss) |
|
$ |
6,702 |
|
|
$ |
(23,938 |
) |
|
$ |
12,177 |
|
|
$ |
(43,187 |
) |
Supplemental information: |
|
|
|
|
|
|
|
|
|
|
|
|
Indirect personnel costs (excluding stock-based compensation) in cost of revenue |
|
$ |
2,024 |
|
|
$ |
2,464 |
|
|
$ |
7,185 |
|
|
$ |
7,422 |
|
Total depreciation and amortization expense |
|
$ |
430 |
|
|
$ |
289 |
|
|
$ |
1,249 |
|
|
$ |
897 |
|
Capital expenditures |
|
$ |
14 |
|
|
$ |
525 |
|
|
$ |
885 |
|
|
$ |
793 |
|
Total assets at period end |
|
$ |
119,044 |
|
|
$ |
111,525 |
|
|
$ |
119,044 |
|
|
$ |
111,525 |
|
|
|
(1) |
Other segment expenses include research and development material and lab expenditures, professional services, marketing, employee travel, facility, insurance, depreciation and amortization and certain other period costs. |
|